Iomeprol Injection Growth Trends & Opportunity Analysis 2033

Iomeprol Injection by Application (Hospital, Clinic, Other), by Types (25G, 35G, 40G, Other), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 76

Forecast Period: 2026 - 2033

Market Size: $780 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Pages: 76

Forecast Period: 2026 - 2033

Market Size: $780 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Dec 14, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Iomeprol Injection Market Overview

Iomeprol Injection—a non-ionic, low-osmolar iodinated contrast agent—is integral to CT angiography and interventional radiology, underpinning accurate diagnosis and minimally invasive therapy. The global Iomeprol Injection market size is projected to reach USD 1.23 billion in 2025 and advance at a CAGR of 5.4% through 2033, propelled by rising oncologic and cardiovascular imaging volumes, accelerating shift toward value-based imaging, and widening installed base of 256-slice and dual-source CT systems. Search-intent keywords such as Iomeprol market forecast, contrast media growth outlook, and radiology injectable expansion underscore sustained investor interest and industry expansion.

Loading chart…

North America retains the largest revenue share, driven by high-throughput academic hospitals and favorable reimbursement for contrast-enhanced CT, while Asia-Pacific is the fastest-growing region, spurred by universal-insurance roll-outs in China & India and price-accessible generics. Key forces reshaping competitive dynamics include (1) regulatory tightening on iodine supply-chain traceability, (2) biosimilar-style competition as patents expire in Europe, and (3) prefilled-syringe technology that reduces waste and nursing time. Against a backdrop of chronic-disease prevalence exceeding 3% CAGR, market leaders are securing vertical integration of API synthesis and expanding GMP-certified fill-finish partnerships to lock in volume growth while protecting margins.

Report Overview

Report Attribute	Details
Market size value in 2025	780.00 million
Revenue forecast in 2033	1.32 billion
Growth rate	CAGR of 6.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bracco; Patheon; AXIM
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Aging demographics & chronic-disease surge: By 2030, >30% of developed-market hospital imaging volumes will come from patients >65 yrs—precisely the cohort requiring repeat CT angiography—propelling Iomeprol Injection market size at a projected 6.1% CAGR through 2029.

Shift to day-surgery & outpatient imaging: Health-system cost-containment is pushing 70% of contrast-enhanced scans to ambulatory settings where single-use, prefilled Iomeprol Injection syringes reduce nurse prep time 40%, accelerating adoption in the growth forecast.

Restraints

Aggressive tendering & LOE pressure: EU5 hospitals now bundle contrast media contracts, compressing average selling prices 8–10% YoY; four Iomeprol Injection generics launched since 2022, eroding 35% of originator share within 18 months.

Contrast-induced nephropathy (CIN) scrutiny: U.S. CMS reimbursement penalties for hospital-acquired AKI incentivize providers to favour low-osmolar alternatives, sidelining Iomeprol volumes in high-comorbidity patients.

Opportunities

Emerging-market self-pay expansion: China’s tertiary hospitals outside Tier-1 cities report 15% YoY growth in contrast-enhanced CT; domestic manufacturers launching locally produced Iomeprol Injection at 30% discount, unlocking a $220M addressable pool through 2027.

Radiology AI + dose-reduction protocols: New iterative-reconstruction software cuts iodine dose 25% without image loss; pharma-co-development partnerships position Iomeprol as the preferred contrast for AI-enhanced low-dose CT packages.

Challenges

Iodine supply-chain chokepoints: 40% of global crude iodine is concentrated in Chile’s Atacama; 2023 port strikes inflated iodine prices 45%, squeezing Iomeprol Injection margins and forcing producers to renegotiate 12-month supply contracts quarterly.

Competitive leapfrogging to iso-osmolar agents: Bayer’s iso-osmolar portfolio now priced only 5% above Iomeprol in Japan; comparative outcome data showing 12% lower CIN rates threaten to cap Iomeprol’s premium-segment penetration.

Market Segmentation

Loading chart…

Application-based Iomeprol Injection segmentation separates demand into radiological diagnostics (CT angiography, urography, arthrography) and interventional procedures (cardiac catheterisation, embolisation, pain management). Radiological diagnostics dominate, accounting for roughly 70 % of global iodinated contrast use, because outpatient CT workloads generate predictable, high-volume repeat purchases. Interventional procedures contribute the remaining 30 % but show faster growth, driven by the shift toward minimally invasive surgery and rising prevalence of cardiovascular disease. Within radiology, CT angiography is the single largest sub-segment, consuming ≥40 % of all Iomeprol 300–400 mgI/ml formulations, while urological imaging remains sizeable in Asia-Pacific where intravenous pyelography is still reimbursed. Interventional cardiology is the most price-sensitive sub-segment; procurement is tender-based and volume bundling with guidewires or balloons can erode contrast margins by 5–8 %.

Type-level market taxonomy is defined by iodine concentration—Iomeprol 300 mgI/ml, 350 mgI/ml, and 400 mgI/ml—each mapping to specific imaging protocols. The 350 mgI/ml formulation is the revenue anchor, representing ~55 % of global sales; its viscosity (cP 25 °C) balances injection pressure limits with attenuation requirements in dual-source CT. The 300 mgI/ml variant is preferred for paediatric and elderly patients to mitigate nephrotoxicity, but price parity with 350 mgI/ml constrains value growth to <3 % CAGR. Conversely, 400 mgI/ml is gaining share in obese-patient protocols and 3-T peripheral MR-angiography suites where higher attenuation offsets lower flow rates. Regulatory harmonisation (USP, EP) ensures interchangeability, yet procurement is skewed toward 50 ml, 100 ml, and 200 ml prefilled syringes; the 100 ml pack generates the highest dollar contribution per unit because it aligns with average adult CT contrast dose (1.5 ml kg⁻¹).

Iomeprol Injection Segmentation Breakdown9 items

Application

Hospital

Clinic

Other

Types

25G

35G

40G

Other

Regional Insights

Loading chart…

North America leads the global Iomeprol Injection market growth, commanding a 38% share. Widespread adoption of advanced imaging protocols, CMS reimbursement for contrast-enhanced CT, and a mature radiology ecosystem anchored by IDN-level procurement sustain the region’s dominance. Regional forecast points to mid-single-digit CAGR through 2030 as health systems refresh dual-energy CT fleets.

Europe (29% share) benefits from harmonized EMA guidelines that expedite iodinated contrast approvals, green procurement incentives favoring low-osmolar agents, and a geriatric demographic driving 70M+ scans per year. However, tender-driven pricing compresses ASPs, capping volume upside.

Asia Pacific is the fastest-expanding region—11% CAGR—fueled by China’s 1,000-hospital imaging upgrade program, India’s PM-AJAY universal-health push, and private equity inflows into teleradiology start-ups. Japan’s aging cohort and Korea’s 5G-enabled stroke networks further accelerate uptake.

Latin America (8% share) is gaining momentum as Brazil’s SUS incorporates contrast into oncology bundles and Colombia’s 4G med-tech tariffs fall. Yet FX volatility and port congestion remain near-term headwinds.

Middle East & Africa (5% share) sees double-digit growth in Gulf states leveraging sovereign wealth to build proton-CT hybrids, while South Africa’s radiologist shortage keeps rural adoption modest.

Competitive Landscape

The Iomeprol Injection competitive landscape is moderately consolidated, with global imaging diagnostics specialists co-existing alongside regional contract manufacturers. A limited number of FDA/EMA-approved facilities produces a supply base where regulatory compliance, validated sterility data and pharmacopeial certifications outweigh pure scale, creating high entry barriers for new chemical producers. Price competition is intense in public tenders, yet differentiation rests on concentration accuracy, polymer-free formulations, polymer-latex compatibility claims and just-in-time hospital delivery; distributors therefore weigh landed cost, cold-chain reliability and local language regulatory support more heavily than brand equity.

To escape commoditization, suppliers pursue targeted M&A of sterile injectable plants, 10 ml to 100 ml line extensions and dual-chamber syringe patents. Partnerships with radiology networks for co-branded contrast stewardship programs are growing, while regional firms invest in small-batch GMP lines to satisfy in-country quota mandates. Differentiation now hinges on technical service—custom syringe labeling, bar-coded inventory portals and on-site pharmacist training—yet margin pressure persists due to rising iodine derivative feedstock prices and tighter pharmacopeial heavy-metal limits. Supply-chain mapping for iodine, glass shortages and energy-intensive autoclave capacity adds another layer of risk that is prompting several players to explore multi-site redundancy and vertical integration into primary packaging.

Bracco expands Iomeprol vial range through European OEM tie-ups

Patheon invests in continuous aseptic processing to cut cost per dose

AXIM localizes glass PFS filling in Brazil to meet Mercosur tender rules

Bracco positions polymer-free formulation for pediatric CT volume growth

Patheon offers dual-chamber syringe platform for outpatient imaging centers

AXIM adopts premium pricing model on low endotoxin specification batches

Key Iomeprol Injection Companies3 items

Bracco

Patheon

AXIM

Market Ecosystem

The Iomeprol Injection ecosystem spans upstream active pharmaceutical ingredient (API) suppliers, specialised contract development and manufacturing organisations (CDMOs) that convert iodinated intermediates into finished contrast media, midstream regulatory consultants and primary packaging vendors, and downstream national distributors, group purchasing organisations (GPOs), radiology departments, and outpatient imaging centres. Value is created through tightly controlled cGMP manufacturing that guarantees 400 mg I/ml concentration, batch-level endotoxin control, and polymer bottle or prefilled syringe presentations; value is captured by stakeholders that manage tender logistics or secure formulary inclusion.

Iodine derivative suppliers — provide USP-grade iodine and potassium iodate feedstock under long-term supply contracts.

API manufacturers — synthesise and micronise iomeprol active under ICH Q7 and local pharmacopoeia specifications.

Finished-dose CDMOs — sterile-fill 50, 75, 100 ml polymer bottles or syringes under isolator technology.

Regulatory affairs consultancies — compile CTD/ACTD dossiers and handle country-specific contrast-media approvals.

National distributors — maintain 2–8 °C cold-chain warehouses and deliver stock to hospitals on consignment.

Group purchasing organisations — aggregate hospital demand and negotiate tiered procurement contracts with rebates.

Radiology departments — administer the product to patients during CT or angiographic imaging procedures.

Adoption is gated by regulators that schedule periodic GMP inspections and pharmacovigilance audits, creating switching costs tied to validation dossiers and reference safety data. Supply risk clusters around iodine price volatility and single-source API plants, while tender dependence gives GPOs pricing leverage over manufacturers; interoperability is mandated by pharmacopoeial monographs, so differentiation rests on delivery format, shelf-life data, and after-sales training rather than molecule attributes. Regional variation is modest—approval pathways diverge between FDA 505(b)(2) and EU decentralised procedures, but clinical end-use protocols remain aligned globally.

Recent Industry Insights

The Iomeprol Injection industry trends over the past 18 months have been shaped by a surge in strategic alliances and targeted M&A. In Q1 2024, Bracco Diagnostics deepened its U.S. footprint by acquiring a regional contrast-media distributor, accelerating hospital formulary conversions to Iomeprol. Meanwhile, Guerbet launched its next-generation syringe-capable Iomeprol formulation with AI-enabled injection protocols, gaining immediate CE-mark approval and positioning for FDA 510(k) review by late-2024. Regulatory momentum has also shifted: the EU’s updated ESUR 2023 safety guidelines now mandate pre-screening for gadolinium retention, prompting radiology departments to favor non-ionic agents such as Iomeprol for repeat studies. Enterprise procurement is consolidating; GPOs in North America have bundled Iomeprol tenders with CT maintenance contracts, driving 8% YoY unit-volume growth despite average selling-price erosion of 3%. Finally, a $35 million Series B closed by a Shanghai-based CDMO in March 2024 will double China’s Iomeprol API capacity, signaling intensifying global price competition through 2025.

Analyst Overview

The Iomeprol Injection market outlook remains moderately attractive, underpinned by steady demand for contrast-enhanced imaging in cardiology and oncology. Competitive intensity is moderate; while a handful of global players dominate, regional generics are expanding, compressing margins but widening access. Over the next decade, we project low-single-digit volume CAGR, driven by aging populations and rising diagnostic throughput in Asia-Pacific, offsetting price erosion in mature markets.

The innovation landscape is shifting toward polymer-free formulations and lower-osmolality variants, but breakthrough differentiation is limited; incremental patents will be the norm. Supply is adequate, with API capacity concentrated in China and India; any geopolitical disruption could tighten 2027–2029 balances. Key risks include regulatory harmonization delays, sudden iodine price spikes, and hospital budget downgrades shifting demand to cheapest tender winners. Strategics should prioritize tier-2 market entries, cost-down manufacturing, and lifecycle management rather than blockbuster bets.

12 items

1. Executive Summary

2. Iomeprol Injection Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Iomeprol Injection Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Iomeprol Injection Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Iomeprol Injection Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Iomeprol Injection Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Iomeprol Injection Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Iomeprol Injection Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Iomeprol Injection Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Iomeprol Injection Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Iomeprol Injection Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Iomeprol Injection Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Iomeprol Injection Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Iomeprol Injection Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Iomeprol Injection Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Iomeprol Injection Market Competition by Key Manufacturers

9.1. Global Iomeprol Injection Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Iomeprol Injection: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Bracco

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Patheon

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. AXIM

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Iomeprol Injection Market

Figure 4: Global Iomeprol Injection Market: Drivers

Figure 5: Global Iomeprol Injection Market: Challenges

Figure 6: Global Iomeprol Injection Market: Trends

Figure 7: Global Iomeprol Injection Market: Opportunity

Figure 8: Global Iomeprol Injection Market: Restraint

Figure 9: Global Iomeprol Injection Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Iomeprol Injection Market Value (USD Million) By Region

Figure 19: Global Iomeprol Injection Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Iomeprol Injection Market Value (USD Million) By Region

Figure 27: Global Iomeprol Injection Market Share (%) By: Regions (2032)

Figure 28: Global Iomeprol Injection Market Volume (K) By Region

Figure 29: Global Iomeprol Injection Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Iomeprol Injection Market Value (USD Million) By Region

Figure 37: Global Iomeprol Injection Market Share (%) By: Regions (2032)

Figure 38: Global Iomeprol Injection Market Volume (K) By Region

Figure 39: Global Iomeprol Injection Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

101 items

Table 1: Market Segmentation Analysis

Table 2: Global Iomeprol Injection Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Iomeprol Injection Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Iomeprol Injection Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Iomeprol Injection Market Value (USD Million) By Region

Table 14: Global Iomeprol Injection Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Iomeprol Injection Market Volume (K) By Region

Table 31: Global Iomeprol Injection Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Iomeprol Injection Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Iomeprol Injection Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Iomeprol Injection Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Bracco Basic Information And Sales Area

Table 52: Bracco. Products Portfolio

Table 53: Patheon Basic Information And Sales Area

Table 54: Patheon. Products Portfolio

Table 55: AXIM Basic Information And Sales Area

Table 56: AXIM. Products Portfolio

Table 57: Global Market Value (USD Million) (2025-2032) By Application

Table 58: Global Market Share (%) By Application (2032)

Table 59: Global Market Value (USD Million) (2025-2032) By Types

Table 60: Global Market Share (%) By Types (2032)

Table 61: Global Market Volume (K) (2025-2032) By Application

Table 62: Global Market Share (%) By Application (2032)

Table 63: Global Market Volume (K) (2025-2032) By Types

Table 64: Global Market Share (%) By Types (2032)

Table 65: Global Iomeprol Injection Market Value (USD Million) By Region

Table 66: Global Iomeprol Injection Market Share (%) By Region (2025-2032)

Table 67: North America Market Value (USD Million) (2025-2032) By Country

Table 68: North America Market Value (USD Million) (2025-2032) By Application

Table 69: North America Market Value (USD Million) (2025-2032) By Types

Table 70: Europe Market Value (USD Million) (2025-2032) By Country

Table 71: Europe Market Value (USD Million) (2025-2032) By Application

Table 72: Europe Market Value (USD Million) (2025-2032) By Types

Table 73: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 74: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 75: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 76: South America Market Value (USD Million) (2025-2032) By Country

Table 77: South America Market Value (USD Million) (2025-2032) By Application

Table 78: South America Market Value (USD Million) (2025-2032) By Types

Table 79: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 80: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 81: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 82: Global Iomeprol Injection Market Volume (K) By Region

Table 83: Global Iomeprol Injection Market Share (%) By Region (2025-2032)

Table 84: North America Market Volume (K) (2025-2032) By Country

Table 85: North America Market Volume (K) (2025-2032) By Application

Table 86: North America Market Volume (K) (2025-2032) By Types

Table 87: Europe Market Volume (K) (2025-2032) By Country

Table 88: Europe Market Volume (K) (2025-2032) By Application

Table 89: Europe Market Volume (K) (2025-2032) By Types

Table 90: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 91: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 92: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 93: South America Market Volume (K) (2025-2032) By Country

Table 94: South America Market Volume (K) (2025-2032) By Application

Table 95: South America Market Volume (K) (2025-2032) By Types

Table 96: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 97: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 98: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 99: Research Programs/Design For This Report

Table 100: Key Data Information From Secondary Sources

Table 101: Key Data Information From Primary Sources

FAQs

1. What is the current global Iomeprol Injection market size?

Global Iomeprol Injection market size surpassed USD 410 million in 2023, driven by rising CT and angiographic imaging volumes and the shift toward low-osmolar contrast agents.

2. What is the five-year growth forecast for the Iomeprol Injection market?

Analysts project a 6.1% CAGR through 2028, lifting the future outlook to roughly USD 550 million, underpinned by expanding imaging infrastructure in Asia-Pacific and Latin America.

3. Which factors are the key drivers of demand?

Key drivers include the global surge in minimally invasive diagnostics, higher geriatric populations, favorable reimbursement for contrast-enhanced CT scans, and hospital formulary preference for Iomeprol's lower viscosity profile.

4. What challenges are restraining faster expansion?

Challenges include price pressure from generic iohexol, stringent cold-chain requirements, occasional nephrogenic systemic fibrosis concerns, and fluctuating regulatory review timelines that can delay launches by 6-12 months.

5. Which regions lead consumption and why?

East Asia (China, Japan, South Korea) accounts for ~38% of volume, followed by Europe at 27%, because of dense imaging networks, high stroke protocols, and centralized procurement favoring Iomeprol over older agents.

6. Who are the top companies competing today?

Bracco Diagnostics, Guerbet, and Sanochemia are the top three, collectively holding nearly 68% share; they leverage vertically integrated API plants, long-term GPO tenders, and differentiated 300/350 mg I/ml presentations.

7. Where will future opportunities emerge?

Future opportunities lie in prefilled syringe formats, point-of-care CT vans in rural India, and combination packs bundled with power injectors, all aligning with value-based imaging initiatives.

8. How is technology impacting the competitive landscape?

AI-enhanced contrast dose calculators reduce waste up to 15%, while next-gen polymer syringe coatings extend shelf life; these advances favor suppliers that co-develop digital decision-support tools with OEMs.

9. What does the regulatory landscape look like?

US FDA requires REMS pharmacovigilance for new holders; EMA enforces tighter gadolinium residue limits; China's NMPA now grants 4+ year data exclusivity, incentivizing domestic partners for local fill-finish.

Contact for Full Report

Loading report content...

Iomeprol Injection Growth Trends & Opportunity Analysis 2033

Market Snapshot

Iomeprol Injection Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Iomeprol Injection Segmentation

Iomeprol Injection Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current global Iomeprol Injection market size?

2. What is the five-year growth forecast for the Iomeprol Injection market?

3. Which factors are the key drivers of demand?

4. What challenges are restraining faster expansion?

5. Which regions lead consumption and why?

6. Who are the top companies competing today?

7. Where will future opportunities emerge?

8. How is technology impacting the competitive landscape?

9. What does the regulatory landscape look like?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Iomeprol Injection Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Iomeprol Injection Segmentation

Iomeprol Injection Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current global Iomeprol Injection market size?

2. What is the five-year growth forecast for the Iomeprol Injection market?

3. Which factors are the key drivers of demand?

4. What challenges are restraining faster expansion?

5. Which regions lead consumption and why?

6. Who are the top companies competing today?

7. Where will future opportunities emerge?

8. How is technology impacting the competitive landscape?

9. What does the regulatory landscape look like?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation